Document is current
Any future updates will be listed below
-
Authors
Riches, Simon https://orcid.org/0000-0002-1427-5561
Kaleva, Ina https://orcid.org/0000-0003-4303-924X
Nicholson, Sarah L. https://orcid.org/0000-0001-5153-7738
Payne-Gill, James https://orcid.org/0000-0003-1802-4695
Steer, Natalie https://orcid.org/0000-0002-0149-4298
Azevedo, Lisa https://orcid.org/0000-0002-9148-7496
Vasile, Ruxandra https://orcid.org/0000-0002-8270-3580
Rumball, Freya https://orcid.org/0000-0002-7099-6523
Fisher, Helen L. https://orcid.org/0000-0003-4174-2126
Veling, Wim https://orcid.org/0000-0002-1364-9779
Valmaggia, Lucia https://orcid.org/0000-0001-6099-8464
-
Funding
Funding for this research was provided by:
Health Innovation Network
- License Information
-
More Information
Article History
Received: 28 November 2023
Revised: 26 January 2024
Accepted: 31 January 2024
First Online: 28 March 2024
Declarations
:
: The study gained ethical approval from King’s College London (HR-19/20–19650).
: All individual participants included in the study provided informed consent for their participation.
: All individual participants included in the study provided informed consent for publication of their data.
: Wim Veling is the cofounder of VRelax BV, the company that has developed the VR application in collaboration with University Medical Center Groningen, and holds shares in VRelax BV. There are no other conflicts of interest.
: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Department of Health, the ESRC, or King’s College London.
